Health & Biotech
An Australian life science company that is the exclusive wholesale distributor for the EAORON branded skin care range to pharmacies, supermarkets and specialist retailers in Australia and New Zealand and owns, produces, designs and distributes its own range of consumer health products under the EZZ brand.
The Company has two distinct and synergistic business models: a wholesale distribution model for the EAORON branded products in the skin care segment; and an integrated model including development, production and distribution for the EZZ branded products in the consumer health segment. Synergy is created by selling the EZZ branded products to established distribution channels previously developed from selling the EAORON branded products
EZZ Life Science formulate, produce, market and distribute health supplements under the brand of EZZ, with a focus on products with significant demand from the market by consumers.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
EZZ’s big growth plans on target after another quarter, oodles of cash and expanding distribution
Health & Biotech
EZZ to focus on combating cancer-causing digestive tract bacteria
Health & Biotech
Stock Insiders: Veteran biotech player joins EZZ on journey to fully integrated life sciences company
Health & Biotech
‘Proven they can deliver’: EZZ ready to be life sciences leader
Health & Biotech
EZZ launches new products to support digestive health
Health & Biotech
ASX Health Stocks: Sigma downgrades earnings, and chairman’s death at Asian American Medical
Health & Biotech
EZZ appoints veteran biotechnology industry player Glenn Cross as chairman
Health & Biotech
‘Untap significant earnings growth’: Equity firm says EZZ Life Science stock is undervalued
Health & Biotech
EZZ to use strong FY21 results to expand growth in international markets
Health & Biotech
Strong FY21 results underpin EZZ’s foothold in growing life sciences sector
News
Closing Bell: ASX retreats despite energy gaining 4.3pc, battery stock Li-S Energy rockets on debut
Health & Biotech
Dr Boreham’s Crucible: Who’s winning and losing in the life sciences IPO Olympiad?
IPO Watch
IPO Watch: Last year it took the ASX 3 quarters to get 18 new listees; this year it took less than 3 months
Health & Biotech
Check Up: Oneview leads healthcare sector after ‘investor awareness’ pact
IPO Watch
IPO Watch: Which ASX sector is most likely to produce the next hot IPO? The answer may surprise you
News
Closing Bell: Today’s biggest small cap movers on the ASX
News